Hackensack, NJ, United States
Hackensack, NJ, United States

Time filter

Source Type

Patent
Champions Oncology | Date: 2015-06-17

The invention relates generally to a humanized mouse model and uses thereof. Specifically, the invention relates to methods for generating, maintaining, and expanding a culture of leukocytes in heterologous animals. This invention also relates to use of these animals as models of human immune system for testing molecules in order to treat a disease or disorder such as cancer.


Patent
Champions Oncology | Date: 2017-04-26

The invention relates generally to a humanized mouse model and uses thereof. Specifically, the invention relates to methods for generating, maintaining, and expanding a culture of leukocytes in heterologous animals. This invention also relates to use of these animals as models of human immune system for testing molecules in order to treat a disease or disorder such as cancer.


News Article | July 17, 2017
Site: www.prnewswire.com

The company will host a conference call to discuss the results that day at 4:30 p.m. EST (1:30 p.m. PST). To participate in the call, please call 866-682-6100 (domestic) or 862-255-5401 (international) ten minutes ahead of the call and give the verbal reference "Champions Oncology." A replay of the call will be available on the Investor tab of the company's website within 72 hours. Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs.  The Company's TumorGraft technology platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or TumorGrafts, in a manner that preserves the biological characteristics of the original human tumor in order to determine the efficacy of a treatment regimen.  The Company uses this technology in conjunction with related services to offer solutions for two customer groups:  Personalized Oncology Solutions, in which results help guide the development of personalized treatment plans, and Translational Oncology Solutions, in which pharmaceutical and biotechnology companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs. TumorGrafts are procured through agreements with a number of institutions in the U.S. and overseas as well as through Champions' Personalized Oncology Solutions business. For more information, please visit www.championsoncology.com.


News Article | July 27, 2017
Site: www.prnewswire.com

Ronnie Morris, CEO of Champions, commented, "We delivered significant gains in revenue and bookings and narrowed our net loss, positioning the company for consistent profitability as we continue to grow in our next fiscal year. Demand for our products and services continues to expand as evidenced by fourth quarter revenue growth of 31%, annual revenue growth of 38%, and annual TOS revenue growth of 49%. At 38%, our revenue growth has far outpaced the minimal 3.2% growth in our largely fixed base of costs as we continue to manage our costs aggressively, reducing our full year operating loss by 50%. Additionally, we recently moved into our new lab facility which we expect will further reduce lab costs. As we look ahead, we are confident revenue will grow by at least 20% in fiscal 2018, setting the stage for continued rapid growth and cash flow positive results." For the fourth quarter of fiscal 2017, revenue was $3.7 million, as compared to $2.8 million for the fourth quarter 2016, an increase of 31.1%. Total operating expenses for the fourth quarter fiscal 2017 and 2016 was $6.1 million and $5.4 million, respectively, an increase of $700,000 or 12.9%. Revenue was $15.4 million and $11.2 million for the twelve months ended April 30, 2017 and 2016, respectively, an increase of $4.2 million or 37.8%. For the fourth quarter of fiscal 2017 and 2016, Champions reported a loss from operations of $2.4 million and $2.6 million, respectively, a decrease of $200,000 or (7.3%). Excluding stock-based compensation of $761,000 and $509,000 for the three months ended April 30, 2017 and 2016, respectively, Champions recognized a loss from operations of $1.6 million and $2.1 million for fourth quarter 2017 and 2016, respectively. For the twelve months ended April 30, 2017 and 2016, Champions reported a loss from operations of $6.8 million and $10.3 million, respectively, a decrease of $3.5 million or (34.2%). Excluding stock-based compensation of $2.7 million and $2.6 million for the twelve months ended April 30, 2017 and 2016, Champions recognized loss from operations of $4.1 million and $7.7 million, respectively. Net cash used in operations was $2.8 million and $6.4 million for the twelve months ended April 30, 2017 and 2016, respectively, a decrease of $3.6 million or (55.7%). The reduction in cash burn is the result of revenue growth and aggressive expense management. The company ended the quarter with $3.3 million of cash and cash equivalents on the balance sheet. Translational Oncology Services (TOS) revenue was $3.4 million and $2.3 million for the three months ended April 30, 2017 and 2016, respectively, an increase of $1.1 million or 48.9%. TOS revenue was $13.7 million and $9.2 million for the twelve months ended April 30, 2017 and 2016, respectively, an increase of $4.5 million or 48.7%. The increase is due to bookings growth in prior quarters, both in the number and size of the studies. TOS cost of sales was $2.3 million and $1.9 million for the three months ended April 30, 2017 and 2016, respectively, an increase of $400,000, or 21.3%. TOS cost of sales was $8.3 million and $6.6 million for the twelve months ended April 30, 2017 and 2016, respectively, an increase of $1.7 million or 25.6%. For the three months ended April 30, 2017 and 2016, gross margin for TOS was 31.3% and 15.6%, respectively. For the twelve months ended April 30, 2017 and 2016, gross margin was 39.6% and 28.5%, respectively. The increase in TOS cost of sales was due to an increase in TOS studies. The improvement in gross margin was due to higher TOS revenue leveraged off the fixed cost component of the lab and effective management of the variable lab costs. Gross margin varies based on timing differences between expense and revenue recognition. While the gross margin improved, there are expenses incurred in advance of future revenue. Personalized Oncology Services (POS) revenue was $366,000 and $585,000 for the three months ended April 30, 2017 and 2016, respectively, a decrease of $219,000 or (37.4%). POS revenue was $1.7 million and $2.0 million for the twelve months ended April 30, 2017 and 2016, respectively, a decrease of $300,000 or (12.%). The decrease is primarily the result of the decline in implant and drug panel revenue of offset by an increase in sequencing revenue. POS cost of sales was $266,000 and $441,000 for the three months ended April 30, 2017 and 2016, respectively, a decrease of $175,000, or (39.7%). POS cost of sales was $1.4 million and $2.1 million for the twelve months ended April 30, 2017 and 2016, respectively, a decrease of $700,000 or (31.8%). For the three months ended April 30, 2017 and 2016, gross margin for POS was 27.3% and 24.6%, respectively. For the twelve months ended April 30, 2017 and 2016, gross margin for POS was 16.7%.and negative (6.6%). The improvement is attributed to the increase in higher margin sequencing revenue and aggressively managing our lab costs. Research and development expense was $1.0 million and $1.2 million for the three months ended April 30, 2017 and 2016, respectively, a decrease of $200,000, or (8.5%). Research and development expense was $4.3 million and $4.2 million for the years ended April 30, 2017 and 2016, respectively an increase of $100,000, or 2.4%. Sales and marketing expense for the three months ended April 30, 2017 and 2016 was $892,000 and $757,000 respectively, an increase of $135,000, or 17.8%. The increase is due to commissions earned in the fourth quarter of fiscal 2017. Sales and marketing expense was $3.3 million and $3.4 million for the years ended April 30 2017 and 2016, respectively a decrease of $100,000, or (5.3%). General and administrative expense was $1.6 million and $1.1 million for the three months ended April 30, 2017 and 2016, respectively, an increase of $500,000 or 41.3%). The increase is due to a one time charge, resulting from an option grant modification, to stock based compensation. General and administrative expense was $5.0 million and $5.2 million for the years ended April 30, 2017 and 2016 respectively, a decrease of $200,000 or (4.1%). The decrease is primarily due to aggressive cost management. The Company will host a conference call today at 4:30 p.m. EST (1:30 p.m. PST) to discuss its fourth quarter financial results. To participate in the call, please call 866-682-6100 (domestic) or 862-255-5401 (international) ten minutes ahead of the call and give the verbal reference "Champions Oncology." Full details of the Company's financial results will be available Monday, July 31, 2017 in the Company's Form 10-K at www.championsoncology.com. See the attached Reconciliation of GAAP net loss to non-GAAP net loss for an explanation of the amounts excluded to arrive at non-GAAP net loss and related non-GAAP net loss per share amounts for the three and twelve months ended April 30, 2017 and 2016. Non-GAAP financial measures provide investors and management with supplemental measures of operating performance and trends that facilitate comparisons between periods before and after certain items that would not otherwise be apparent on a GAAP basis. Certain unusual or non-recurring items that management does not believe affect the Company's basic operations do not meet the GAAP definition of unusual or non-recurring items. Non-GAAP net loss and non-GAAP loss per share are not, and should not be viewed as a substitute for similar GAAP items. Champions' defines non-GAAP dilutive loss per share amounts as non-GAAP net loss divided by the weighted average number of diluted shares outstanding. Champions' definition of non-GAAP net loss and non-GAAP diluted loss per share may differ from similarly named measures used by others. Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs.  The Company's TumorGraft technology platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or TumorGrafts, in a manner that preserves the biological characteristics of the original human tumor in order to determine the efficacy of a treatment regimen.  The Company uses this technology in conjunction with related services to offer solutions for two customer groups:  Personalized Oncology Solutions, in which results help guide the development of personalized treatment plans, and Translational Oncology Solutions, in which pharmaceutical and biotechnology companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs. TumorGrafts are procured through agreements with a number of institutions in the U.S. and overseas as well as through Champions' Personalized Oncology Solutions business. For more information, please visit www.championsoncology.com. This press release may contain "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties.  Champions Oncology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements.  One should not place undue reliance on these forward-looking statements.  The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors.  See Champions Oncology's Form 10-K for the fiscal year ended April 30, 2017 for a discussion of such risks, uncertainties and other factors.  Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Oncology's future results, levels of activity, performance or achievements may not meet these expectations.  The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Oncology's expectations, except as required by law.


Home > Press > Harris & Harris Group Issues Business Update and Reports Financial Statements as of September 30, 2016 Abstract: Harris & Harris Group, Inc. (NASDAQ:TINY), reported today that, as of September 30, 2016, its net asset value and net asset value per share were $75,322,949 and $2.44, respectively. The Company's Quarterly Report on Form 10-Q may be accessed at http://ir.hhvc.com/sec.cfm . Review of Third Quarter 2016 During the third quarter of 2016, we continued to take steps to position the Company for potential future growth. We believe a number of accomplishments, including those by our portfolio companies during the quarter, have the potential to contribute to this goal. These steps and accomplishments include: We increased our investment income by 132 percent and decreased our net operating loss by 46 percent during the third quarter of 2016 as compared with the third quarter of 2015. We increased our investment income by 97 percent and decreased our net operating loss by 41 percent during the first nine months of 2016 as compared with the first nine months of 2015. A number of our portfolio companies announced financings and/or business milestones during the quarter including: D-Wave Systems, Inc., announced details of its most advanced quantum computing system, featuring a new 2,000 qubit processor. The company made the announcement at its inaugural users group conference in Santa Fe, New Mexico. D-Wave Systems, Inc., also announced the formation of D-Wave Government Inc., a U.S. subsidiary formed to provide D-Wave's quantum computer systems to the U.S. government. The company also announced the members of the subsidiary's independent board, which include prominent executives with extensive experience at U.S. government agencies including the Department of Energy, the Department of Defense, the National Science Board, the Defense Science Board and the Intelligence Community. HZO, Inc., announced a collaboration with Rakuten Kobo to protect its latest eReader, the Kobo Aura ONE. Mersana Therapeutics, Inc., announced that it has clearance from the FDA to begin a Phase 1 clinical trial for its antibody-drug conjugate therapy for cancer. In conjunction with this clearance, the company received a $20 million milestone payment from Takeda. The following announcements were made by companies we are building that are focused on precision health and medicine. Interome, Inc., announced that it is a co-organizer of the UnDx Consortium™. This organization brings together five precision medicine technology providers and prominent experts from medical centers and universities across the country to collaborate in an effort to produce new hypotheses for a set of seven patients struggling with undiagnosed diseases. The UnDx Consortium met to explore results of cutting-edge tests analyzing samples from these patients and their families. That meeting is the beginning of what is expected to evolve into an ongoing forum to explore the potential of combining precision medicine technologies to diagnose and treat disease. Muses Labs, Inc., presented data from a pilot study of its MEND Protocol for the treatment of early Alzheimer's disease at the Alzheimer's Association International Conference 2016. MEND Protocol is a multi-step cognitive evaluation process that uses advanced data processing technology to first assess which risk factors are present in an individual. Muses Labs, Inc., and Metabolon, Inc., announced a partnership to study and apply metabolomics in individuals with pre- and early-symptomatic cognitive decline and Alzheimer's disease. The companies stated that they expect to bring new clinical trial services and updated care protocols to the market. Metabolon, Inc., announced that it closed a round of financing of $15 million from a new investor, Essex Woodlands. EchoPixel, Inc., announced that its medical virtual reality system is ready for clinical implementation. The system is being distributed to customers in collaboration with the HP Zvr Interactive Virtual Reality Display and workstation. We also faced the following challenges during this quarter: Net asset value per share decreased from $2.88 as of December 31, 2015, to $2.44 as of September 30, 2016. Our price per share decreased from $2.20 as of December 31, 2015, to $1.39 as of September 30, 2016, and $1.25 as of November 8, 2016. Senova Systems, Inc., sold substantially all of its assets to an undisclosed buyer for an up-front payment and potential future milestone payments. Even if all of the milestone payments are received in full, we do not expect to recover our cost basis of approximately $4 million. The values of public equities, particularly those of microcapitalization companies, are highly volatile. The price per share and market capitalization of Adesto Technologies Corporation decreased in value from $3.28 at June 30, 2016, to $2.22 at September 30, 2016, and closed at $2.05 at November 8, 2016. Champions Oncology, Inc., decreased in value from $2.15 at June 30, 2016, to $1.68 at September 30, 2016, and closed at $1.70 at November 8, 2016. Enumeral Biomedical Holdings, Inc., decreased in value from $0.20 at June 30, 2016, to $0.18 at September 30, 2016, and closed at $0.14 at November 8, 2016. While the price per share and market capitalization of OpGen, Inc., increased in value from $1.52 at June 30, 2016, to $1.64 at September 30, 2016, the price per share of each company's common stock continues to trade significantly below the price per share at the time of each company's initial public listing. Additionally, the values of comparable public market companies that are inputs in determining the values of certain of our portfolio companies also decreased during the quarter. Our own stock price has been under considerable pressure from these and other headwinds. Even though the financings of some of our portfolio companies may have occurred at increases in price per share from prior rounds of financing, such increases may not be reflected in full in our values owing to other rights and preferences afforded to investors in those rounds of financing. This challenge, in part, limited the positive potential contribution to our net asset value per share by companies that completed such rounds of financing during the third quarter of 2016. Additional accomplishments and challenges can be found in the Management's Discussion and Analysis section of our Quarterly Report. As we have stated previously in our letters to shareholders and in our blog posts, our net asset value is and will continue to be impacted significantly by the volatility of the public markets as our portfolio companies mature through two mechanisms: 1) the values of publicly traded comparable companies become significant inputs to value; and 2) our portfolio companies become publicly traded. As of the end of the prior quarter, this volatility contributed significantly to a sharp decrease in our net asset value. As of the end of this quarter, the net decreases in value owing to our publicly traded portfolio companies were offset by net increases in our privately held portfolio companies. Please join us for our third quarter of 2016 shareholder update call on Tuesday, November 15, 2016, at 10:00 a.m. Eastern Time. SUMMARY OF FINANCIAL POSITION September 30, 2016 December 31, 2015 September 30, 2015 (Unaudited) (Audited) (Unaudited) Total Assets $ 82,422,674 $ 96,461,286 $ 94,158,008 Net Assets $ 75,322,949 $ 88,711,671 $ 86,974,196 Net Asset Value Per Share $ 2.44 $ 2.88 $ 2.80 Shares Outstanding 30,880,829 30,845,754 31,022,866 About Harris & Harris Group Harris & Harris Group is a publicly traded, internally managed business development company that builds transformative companies from disruptive science. Detailed information about Harris & Harris Group and its holdings can be found on its website at www.HHVC.com, on Facebook at www.facebook.com/harrisharrisvc and by following on Twitter @harrisandharrisgroup. This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the Company's current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. Please see the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2015, as well as subsequent filings, filed with the Securities and Exchange Commission for a more detailed discussion of the risks and uncertainties associated with the Company's business, including, but not limited to, the risks and uncertainties associated with venture capital investing and other significant factors that could affect the Company's actual results. Except as otherwise required by Federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties. The references to the websites www.HHVC.com and www.Facebook.com have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. The Company is not responsible for the contents of third party websites. For more information, please click If you have a comment, please us. Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.


News Article | November 17, 2016
Site: www.prnewswire.com

HACKENSACK, N.J., Nov. 17, 2016 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today the signing of a $2 million contract with a large...


HACKENSACK, N.J., Nov. 29, 2016 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the second quarter ended...


HACKENSACK, N.J., Nov. 23, 2016 /PRNewswire/ -- Champions Oncology (NASDAQ: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational...


NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky announces it has commenced an investigation of Champions Oncology, Inc. concerning possible breaches of Delaware law.


HACKENSACK, N.J., Feb. 16, 2017 /PRNewswire/ -- Champions Oncology, Inc. (NASDAQ: CSBR), a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced the addition of new cohorts of PDX...

Loading Champions Oncology collaborators
Loading Champions Oncology collaborators